8-K current report · filed Oct 29, 2026

Indivior Pharmaceuticals, Inc. (INDV) 8-K Current Report: October 29, 2026

Item 2.02Item EX-99.1INDV overview

Short answer

Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal period ended September 30, 2026, covering Indivior’s third quarter results.

Indivior Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal period ended September 30, 2026, covering Indivior’s third quarter results
  • Results furnished in Exhibit 99.1, the company’s press release
  • Investors should review Exhibit 99.1 for revenue, earnings, guidance, and operating trends

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $356M, up 13% YoY, led by SUBLOCADE revenue $267M, up 22%
  • Record adjusted EBITDA $211M, up 76%, with margin 59%, up 2,100 basis points
  • GAAP net income $137M, or $1.12 diluted EPS, versus $42M and $0.33 in Q3 2025
  • Cash and investments $332M, while current debt increased to $488M ahead of the merger
  • Supernus merger expected November 2, with combined company trading as SUPN from November 3 and standalone guidance ending at closing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Indivior Pharmaceuticals, Inc. 8-K filings

Get the next INDV 8-K as it lands

Follow INDV for push alerts, or ask the research agent what this filing means.